Literature DB >> 21911649

Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study.

Samira Khan1, Paul T Finger, Guo-Pei Yu, Lubna Razzaq, Martine J Jager, Rob J W de Keizer, Per Sandkull, Stefan Seregard, Daniel Gologorsky, Amy C Schefler, Timothy G Murray, Tero Kivelä, Gian Paolo Giuliari, Hugh McGowan, E Rand Simpson, Christine Corriveau, Sarah E Coupland, Bertil E Damato.   

Abstract

OBJECTIVE: To collaborate with multiple centers to identify representative epidemiological, clinical, and pathologic characteristics of melanoma of the iris. This international, multicenter, Internet-assisted study in ophthalmic oncology demonstrates the collaboration among eye cancer specialists to stage and describe the clinical and pathologic characteristics of biopsy-proven melanoma of the iris.
METHODS: A computer program was created to allow for Internet-assisted multicenter, privacy-protected, online data entry. Eight eye cancer centers in 6 countries performed retrospective chart reviews. Statistical analysis included patient and tumor characteristics, ocular and angle abnormalities, management, histopathology, and outcomes.
RESULTS: A total of 131 patients with iris melanoma (mean age, 64 years [range, 20-100 years]) were found to have blue-gray (62.2%), green-hazel (29.1%), or brown (8.7%) irides. Iris melanoma color was brown (65.6%), amelanotic (9.9%), and multicolored (6.9%). A mean of 2.5 clock hours of iris was visibly involved with melanoma, typically centered at the 6-o'clock meridian. Presentations included iritis, glaucoma, hyphema, and sector cataract. High-frequency ultrasonography revealed a largest mean tumor diameter of 4.9 mm, a mean maximum tumor thickness of 1.9 mm, angle blunting (52%), iris root disinsertion (9%), and posterior iris pigment epithelium displacement (9%). Using the American Joint Commission on Cancer-International Union Against Cancer classification, we identified 56% of tumors as T1, 34% of tumors as T2, 2% of tumors as T3, and 1% of tumors as T4. Histopathologic grades were G1-spindle (54%), G2-mixed (28%), G3-epithelioid (5%), and undetermined (13%) cell types. Primary treatment involved radiation (26%) and surgery (64%). Kaplan-Meier analysis found a 10.7% risk of metastatic melanoma at 5 years.
CONCLUSIONS: Iris melanomas were most likely to be brown and found in the inferior quadrants of patients with light irides. Typically small and unifocal, melanomas are commonly associated with angle blunting and spindle cell histopathology. This multicenter, Internet-based, international study successfully pooled data and extracted information on biopsy-proven melanoma of the iris.

Entities:  

Mesh:

Year:  2011        PMID: 21911649     DOI: 10.1001/archophthalmol.2011.286

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  20 in total

1.  Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Authors:  Aline I Riechardt; Julian P Klein; Dino Cordini; Jens Heufelder; Matus Rehak; Ira Seibel; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-20       Impact factor: 3.117

2.  Trabeculectomy in patients with uveal melanoma after proton beam therapy.

Authors:  Aline I Riechardt; Dino Cordini; Matus Rehak; Annette Hager; Ira Seibel; Alexander Böker; Enken Gundlach; Jens Heufelder; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-10       Impact factor: 3.117

3.  Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre.

Authors:  Aakriti Garg Shukla; Sarangdev Vaidya; Antonio Yaghy; Maura Di Nicola; Swathi Kaliki; Enzo Fulco; Jonathan S Myers; Jerry A Shields; Carol L Shields
Journal:  Eye (Lond)       Date:  2022-04-05       Impact factor: 3.775

Review 4.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

5.  Gene expressing profiling of iris melanomas.

Authors:  J William Harbour; David Wilson; Paul T Finger; Lori A Worley; Michael D Onken
Journal:  Ophthalmology       Date:  2013-01       Impact factor: 12.079

6.  Orbital recurrence of iris melanoma 21 years after enucleation.

Authors:  Emilie Bergeron; Nadia Lihimdi; Dan Bergeron; Solange Landreville
Journal:  BMJ Case Rep       Date:  2017-09-07

7.  Novel Eye Plaque Designs for Brachytherapy of Iris and Ciliary Body Melanoma and the First Clinical Application.

Authors:  Wu Liu; Jenna May Kim; Benjamin K Young; Ravinder Nath; Zhe Chen; Roy H Decker; Melvin A Astrahan; Renelle Pointdujour-Lim
Journal:  Ocul Oncol Pathol       Date:  2018-10-11

Review 8.  Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

9.  Selective Intra-Arterial Embolization for Advanced Extrascleral Uveal Melanoma.

Authors:  Víctor M Villegas; Mariola Monagas; Joseph Campbell; Timothy G Murray; Luis Serrano
Journal:  Ocul Oncol Pathol       Date:  2017-07-19

10.  Iris melanoma in children: Current approach to management.

Authors:  John P McLaughlin; Adrian T Fung; Jerry A Shields; Carol L Shields
Journal:  Oman J Ophthalmol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.